Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study
Objectives: Recurrent and progressive small cell lung cancer (SCLC) has a very poor prognosis, and treatment options are limited. Combination of irinotecan with ifosfamide ( I-I regimen) in SCLC has limited preliminary data. In this study, we aimed to evaluate the efficacy and toxicity of I-I regimen in patients with previously treated SCLC.
Methods: A total of 25 patients were retrospectively reviewed. Ifosfamide dose was 1500 mg/m2 / per day, days 1-3, irinotecan 80 mg/m2 per day days 1.8 and 15 every four weeks.
Results: Median age of patients was 55 years (range 42-80). Median chemotherapy cycles were 3 (range 1-7). The frequency of the second, third and fourth line treatments were 68%, 24%, and 8% respectively. Partial remission was obtained in 15 patients (60%) and complete remission in one patient (4%). Median progression free survival (PFS) and overall survival (OS) figures were 7.8 and 11.1 months, respectively. Granulocyte colony stimulating factor (G-CSF) was used in 40% of patients. Grade 3-4 anemia, leukopenia, and thrombocytopenia were seen in 20%, 36% and 12% of these cases, respectively.
Conclusion: Ifosfamide and irinotecan combination is an effective and a tolerable treatment option for patients with platinum refractory SCLC.
1.Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:5–21. [CrossRef]
2. Asai N, Ohkuni Y, Kaneko N, Yamaguchi E, Kubo A. Relapsed small cell lung cancer: treatment options and latest developments. Ther Adv Med Oncol 2014;6:69–82. [CrossRef]
3. Paccagnella A, Favaretto A, Brandes A, Ghiotto C, Fornasiero A, Volpi A, Pappagallo G, et al. Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. Cancer 1990;65:2631–4. [CrossRef]
4. Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/ mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991;42:428–67. [CrossRef]
5. Kosmidis P, Mylonakis N, Fountzilas G, Pavlidis N, Samantas E, Karabelis A, et al. A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group. Ann Oncol 1996;7:517–20. [CrossRef]
6. Graziano SL, Valone FH, Herndon JE 2nd, Crawford J, Richards F 2nd, Rege VB,Clamon G, Green MR. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 1996;14:315–29. [CrossRef]
7. Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, et al. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1998;16:1388–96. [CrossRef]
8. Jacot W, Pujol JL, Chakra M, Molinier O, Bozonnat MC, Gervais R, et al. Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients. Lung Cancer 2012;75:213–6.
9. Boni C, Pagano M, Baldi L, Gnoni R, Braglia L, Savoldi L, et al. Pei regimen: a therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases. J Transl Med 2015;13:130. [CrossRef]
10. Lee HS, Lee YG, Koo DH, Oh S, Nam H, Song JU, et al. Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. Cancer Chemother Pharmacol 2015;76:933–7. [CrossRef]
11. Tanaka I, Kawada K, Morise M, Hase T, Hayashi H, Sokai A, et al. A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting. Cancer Chemother Pharmacol 2018;81:339–345. [CrossRef]
12. Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010;5:867–73. [CrossRef]
13. Xu F, Ren X, Chen Y, Li Q, Li R, Chen Y, et al. Irinotecan-platinum combination therapy for previously untreated extensivestage small cell lung cancer patients: a meta-analysis. BMC Cancer 2018;18:808. [CrossRef]
14. Liu ZL, Wang B, Liu JZ, Liu WW. Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis. J Cancer Res Ther 2018;14(Supplement):S1076–S1083.
15. Ichiki M, Gohara R, Rikimaru T, Kitajima T, Fujiki R, Shimada A, et al. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study. Chemotherapy 2003;49:200–5. [CrossRef]
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16. [CrossRef]
17. National Cancer Institute. Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc. htm.
18. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958;53:457–81.
19. Amarasena IU, Chatterjee S, Walters JA, Wood-Baker R, Fong KM. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 2015;CD006849. [CrossRef]
20. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658–67. [CrossRef]
21. O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441–7.
22. Schuette W, Nagel S, Juergens S, Bork I, Wollschlaeger B, Schaedlich S, et al. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer 2005;7:133–7. [CrossRef]
23. Kubota K, Nishiwaki Y, Kakinuma R, Hojo F, Matsumoto T, Ohmatsu H, et al. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 1997;15:292–6. [CrossRef]
24. Yang H, Ma Y, Liu Z, Wang Z, Han B, Ma L. Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis. Mol Clin Oncol 2015;3:420–424. [CrossRef]
25. Han JY, Kim HY, Lim KY, Han JH, Lee YJ, Kwak MH, et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer 2013;79:137–42. [CrossRef]
26. Gandhi L, Heist RS, Lucca JV, Temel JS, Fidias P, Morse LK, et al. A phase II trial of pazopanib in relapsed/refractory small cell lung cancer (SCLC). 2012 ASCO Annual Meeting. J Clin Oncol 2012;30(Suppl.): abstract 7099. [CrossRef]
27. Lee P, Alvarez RH, Melichar B, Adenis A, Bennouna J, Schusterbauer C, et al. Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: preliminary phase II results. 2012 ASCO Annual Meeting. J Clin Oncol 2012;30(Suppl.): abstract 3010. [CrossRef]
28. Arcaro A. Targeted therapies for small cell lung cancer: Where do we stand? Crit Rev Oncol Hematol 2015;95:154–64. [CrossRef]
29. Li Q, Yuan D, Ma C, Liu Y, Ma L, Lv T, et al. A new hope: the immunotherapy in small cell lung cancer. Neoplasma 2016;63:342–50.